hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06330311 id: 20/551-EC briefTitle: Effectiveness of Whole-Body Vibration acronym: WBVibration overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-29 date: 2024-09-29 date: 2024-09-29 date: 2024-03-26 date: 2024-04-12 name: Universidad Complutense de Madrid class: OTHER name: Hospital Infantil Universitario Niño Jesús, Madrid, Spain briefSummary: Cerebral Palsy is the most common cause of severe physical disability in childhood and may present difficulties and limitations that will have an impact on their independence and integration in all social areas.
The aim of this study is to assess the effectiveness on motor function and spasticity of the lower limbs by adding an intervention with WBV to an evidence-based multimodal physiotherapy treatment in children with CP. conditions: Spastic Cerebral Palsy conditions: Physical Therapy Modalities conditions: Vibration; Exposure conditions: Lower Extremity Weakness, Spastic conditions: Muscle Spasticity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The participants will be randomly allocated to experimental or control group primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The principal investigator will be blinded to the randomization, patient assessment, and data analysis. whoMasked: INVESTIGATOR count: 30 type: ACTUAL name: Physiotherapy measure: GROSS MOTOR FUNCTION MEASURE 88 (D and E dimensions) measure: GROSS MOTOR FUNCTION MEASURE 88 (D and E dimensions) measure: GROSS MOTOR FUNCTION MEASURE 88 (D and E dimensions) measure: GROSS MOTOR FUNCTION MEASURE 88 (D and E dimensions) measure: Modified Ashworth Scale (MAS) measure: Modified Ashworth Scale (MAS) measure: Modified Ashworth Scale (MAS) measure: Modified Ashworth Scale (MAS) measure: 6 Minute Walking Test (6MWT) measure: 6 Minute Walking Test (6MWT) measure: 6 Minute Walking Test (6MWT) measure: 6 Minute Walking Test (6MWT) measure: Dynamometry measure: Dynamometry measure: Dynamometry measure: Dynamometry measure: Mini-Balance Evaluation System Test measure: Mini-Balance Evaluation System Test measure: Mini-Balance Evaluation System Test measure: Mini-Balance Evaluation System Test measure: Cerebral Palsy Quality of Life questionnaire (CP-QOL) measure: Cerebral Palsy Quality of Life questionnaire (CP-QOL) measure: Cerebral Palsy Quality of Life questionnaire (CP-QOL) sex: ALL minimumAge: 8 Years maximumAge: 14 Years stdAges: CHILD facility: María José Díaz Arribas city: Madrid zip: 28040 country: Spain lat: 40.4165 lon: -3.70256 hasResults: False
nctId: NCT06330298 id: 202000479 briefTitle: Improving Social Cognition and Social Behaviour in Various Brain Disorders acronym: T-ScEmo4ALL overallStatus: RECRUITING date: 2021-05-31 date: 2025-01-31 date: 2025-01-31 date: 2024-03-26 date: 2024-04-16 name: University Medical Center Groningen class: OTHER briefSummary: Impairments in aspects of social cognition are disorder-transcending: these have been demonstrated in various neurological disorders, such as traumatic brain injury (TBI), stroke, brain tumours (both low grade glioma's and meningioma's) and multiple sclerosis (MS). Social cognition involves processing of social information, in particular the abilities to perceive social signals, understand others and respond appropriately (Adolphs 2001). Crucial aspects of social cognition are the recognition of facial expressions of emotions, perspective taking (also referred to as mentalizing or Theory of Mind), and empathy. Impairments in social cognition can have a large negative impact on self-care, communication, social and professional functioning, and thus on quality of life of patients.
Unfortunately, up till now there are no evidence based, transdiagnostic treatment possibilities available for these impeding social cognition impairments in neurological patient groups, other than TBI. Therefore the aim of the present study is to investigate whether T-ScEmo is effective for social cognition disorders in patients with different neurological impairments, such as stroke (including subarachnoidal haemorrhage (SAH)), brain tumours, MS, infection (meningitis, encephalitis) and other. The secondary objective is to determine which patient related factors are of influence on treatment effectiveness. In short, hopefully this study can contribute to a treatment possibility for social cognition disorders for all patients with various neurological disorders.
It is expected that T-ScEmo will be effective for various neurological disorders, based on previous research of Westerhof-Evers et al. (2017, 2019). Since social cognition disorders within patients with traumatic brain injury do all have the same ethiology it is expected that the treatment will show the same effects for patients with various neurological disorders. Therefore it is expected that patients will improve on social cognition, social participation and quality of life and social behaviour, that these results will last over time. conditions: Stroke conditions: Multiple Sclerosis conditions: Brain Tumor studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Experimental condition T0, baseline measurement at point of inclusion (at least \> 6 months post-acute injuries) T1, post measurement within 2 weeks after treatment T2, follow-up measurement within 3 - 5 months after treatment
In addition, a group of patients with Traumatic Brain Injury will receive T-ScEmo following regular care. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The neuropsychologist who leads T1 and T2 measurements will be masked for the fact of which patient will be draw in which clinical condition (experimental group or control group), however this cannot be guaranteed since patients may talk about their experience. whoMasked: INVESTIGATOR count: 84 type: ESTIMATED name: Treatment social cognition and emotion regulation (T-ScEmo) measure: Change in social behaviour examined by proxy measure: Social cognition: Emotion recognition as assessed using the Eckman-60 faces test measure: Social cognition: Theory of Mind as assessed using the Happé cartoons test measure: Social cognition: Theory of Mind as assessed using the Faux Pas test measure: Social cognition: assessed using the Hailing Sentence Completion Test measure: Demographic information measure: Self-rated social behaviour as assessed using the Dysexecutive questionnaire Social Scales. measure: Self-rated social behaviour as assessed using the Interpersonal Reactivity Index measure: Self-rated social behaviour as assessed using The Dutch version of the BAFQ social scales measure: Proxy-rated social behaviour as assessed using the Interpersonal Reactivity Index measure: Proxy-rated social behaviour as assessed using the Socioemotional Dysfunction Scale measure: Proxy-rated social behaviour as assessed using the Dutch version of the BAFQ social scales measure: Alexithymia measure: Life satisfaction measure: (Social) participation as assessed using the Utrecht Scale for Evaluation of Rehabilitation measure: (Social) participation as assessed using the Impact on Participation and Autonomy scale measure: Mood and anxiety measure: Caregiving burden measure: Goal attainment measure: Executive functioning as assessed using the Controlled Oral Word Association Test measure: Executive functioning assessed using the Key Search Test measure: Verbal memory measure: Working memory measure: Language measure: Mental speed and attention as assessed using the Trail Making Test measure: Mental speed and attention as assessed using the Symbol Digit Modalities Test measure: Premorbid intelligence measure: Fatigue measure: Health limitations measure: Coping sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Deventer Hospital status: RECRUITING city: Deventer state: Overijssel zip: 7416SE country: Netherlands name: M.J.J. Gerritssen, dr. role: CONTACT lat: 52.255 lon: 6.16389 facility: University Medical Center Groningen status: RECRUITING city: Groningen zip: 9700VB country: Netherlands name: Amber Heegers, MSc. role: CONTACT phone: +3150 361 4666 email: a.heegers@umcg.nl lat: 53.21917 lon: 6.56667 hasResults: False
nctId: NCT06330285 id: e learning pgme/cpet briefTitle: Comparison of E-Learning and Face-to-Face Learning in Cardiopulmonary Exercise Test Training overallStatus: NOT_YET_RECRUITING date: 2024-03-22 date: 2024-06-15 date: 2024-08-15 date: 2024-03-26 date: 2024-03-26 name: Kayseri City Hospital class: OTHER_GOV name: TC Erciyes University briefSummary: The main purpose of this study is to compare the effect of teaching Cardiopulmonary Exercise Test (CPET) via e-learning and face-to-face to doctors receiving postgraduate medical education (PGME). conditions: Exercise Test conditions: Learning studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 50 type: ESTIMATED name: e-learning name: face to face learning measure: Open-Ended Achievement Test measure: Adult Motivation Scale measure: Distance Education Attitude Scale in Lifelong Learning measure: Cognitive Flexibility Scale measure: State and Trait Anxiety Scale sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06330272 id: UCeuma briefTitle: Accuracy of Spectrophotometry in Hypomineralized Lesions Treated With CPP-ACPF Dental Mousse: Clinical Study acronym: ASHLTDMCS overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-01 date: 2025-03 date: 2024-03-26 date: 2024-03-28 name: Meire Coelho Ferreira class: OTHER name: Fundação de Amparo à Pesquisa e Desenvolvimento Científico do Maranhão briefSummary: MIH is a condition with considerable prevalence in the child population. This structural defect, represented by a change in the color of the enamel, can be accompanied by structural loss and great sensitivity. Remineralizing agents have been used to strengthen compromised enamel. The objective of the study will be to measure the accuracy of a spectrophotometer (VITA Easyshade V) in determining the mineralization of IMH lesions by a CPP-ACPF dental mousse. conditions: Molar Incisor Hypomineralization studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: MIH lesions will receive prophylaxis with pumice stone before application of CPP-ACPF-based dental foam (Tooth Mousse PlusTM, GC Corporation, Tokyo, Japan).
The application of Tooth Mousse Plus to the MIH lesion will be carried out under relative isolation and with the aid of a microbrush. The cream will remain on the surface for 1 minute. The application will be carried out once a week, for four consecutive weeks. primaryPurpose: TREATMENT masking: NONE count: 98 type: ESTIMATED name: Application of dental mousse based on CPP-ACPF measure: To measure the accuracy of a spectrophotometer (VITA Easyshade V) in determining the mineralization of IMH lesions by a CPP-ACPF dental mousse sex: ALL minimumAge: 7 Years maximumAge: 9 Years stdAges: CHILD facility: Josue Montello, Universidade Ceuma city: São Luis state: Maranhão zip: 65075-120 country: Brazil lat: -2.52972 lon: -44.30278 hasResults: False
nctId: NCT06330259 id: new AMH assay briefTitle: Does the AMH Concentration Depend on the Menstrual Cycle? acronym: AMH overallStatus: COMPLETED date: 2017-07-01 date: 2018-06-30 date: 2019-12-31 date: 2024-03-26 date: 2024-04-01 name: University of Basel class: OTHER name: Roche Diagnostics briefSummary: During two none subsequent natural menstrual cycles healthy female participants will be subjected every second day to blood sampling and 3D-ultrasound examinations. Together with four other key hormones the concentration of AMH (anti-Muellerian Hormone) will be measured in the serum. conditions: Reproductive Sterility studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ACTUAL name: menstrual cycle monitoring measure: AMH Elecsys Assay measure: Effect of handling of the serum on measured AMH concentrations measure: 3D ultrasound of both ovaries sex: FEMALE minimumAge: 18 Years maximumAge: 39 Years stdAges: ADULT facility: Christian De Geyter city: Basel zip: 4031 country: Switzerland lat: 47.55839 lon: 7.57327 hasResults: False
nctId: NCT06330246 id: IRB300005280 id: R01DK137784 type: NIH link: https://reporter.nih.gov/quickSearch/R01DK137784 briefTitle: O. Formigenes Colonization in Calcium Oxalate Kidney Stone Disease overallStatus: RECRUITING date: 2024-05-01 date: 2030-12-31 date: 2031-12-31 date: 2024-03-26 date: 2024-04-03 name: University of Alabama at Birmingham class: OTHER name: University of Texas Southwestern Medical Center name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) briefSummary: The goal of this trial is to test if colonization with the gut bacteria Oxalobacter formigenes leads to a reduction in urinary oxalate excretion in patients with calcium oxalate kidney stone disease.
* ingest a preparation of live Oxalobacter formigenes to induce colonization with Oxalobacter formigenes conditions: Kidney Stone conditions: Kidney Calculi conditions: Urolithiasis conditions: Urolithiasis, Calcium Oxalate conditions: Nephrolithiasis conditions: Nephrolithiasis, Calcium Oxalate conditions: Oxalate Urolithiasis conditions: Oxaluria studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SEQUENTIAL primaryPurpose: BASIC_SCIENCE masking: NONE count: 40 type: ESTIMATED name: Low oxalate fixed diets pre-colonization name: Moderately high oxalate fixed diets pre-colonization name: Colonization with Oxalobacter formigenes name: Low oxalate fixed diets post-colonization name: Moderately high oxalate fixed diets post-colonization measure: Change in urinary oxalate excretion following colonization with Oxalobacter formigenes measure: Sustainability of colonization with Oxalobacter formigenes sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Alabama at Birmingham status: RECRUITING city: Birmingham state: Alabama zip: 35294 country: United States name: Sonia Fargue, PhD role: CONTACT phone: 205-975-6932 email: sfargue@uab.edu name: Research Coordinator role: CONTACT phone: 2059345712 email: kidneystone@uabmc.edu name: Sonia Fargue, PhD role: PRINCIPAL_INVESTIGATOR lat: 33.52066 lon: -86.80249 facility: UTSW status: RECRUITING city: Dallas state: Texas zip: 75390 country: United States name: Naim Maalouf, MD role: CONTACT email: Naim.Maalouf@UTSouthwestern.edu name: Esperanza Jackson role: CONTACT email: Esperanza.Jackson@UTSouthwestern.edu name: Naim Maalouf, MD role: PRINCIPAL_INVESTIGATOR lat: 32.78306 lon: -96.80667 hasResults: False
nctId: NCT06330233 id: YJiang briefTitle: Different Amounts of Moxibustion in the Treatment of DPN: A Clinical RCT Study overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-04-07 date: 2026-12-31 date: 2024-03-26 date: 2024-03-26 name: Zhejiang Chinese Medical University class: OTHER_GOV name: The First Affiliated Hospital of Zhejiang Chinese Medical University briefSummary: This study is designed to provide the treatment plan for moxibustion for diabetic peripheral neuropathy (DPN) and provide a reference for clinical moxibustion for DPN. The patients will be randomly assigned to three clinical centers each center 44, then they will be distributed equally into 4 groups, which include the conventional treatment group and the moxibustion different minutes (5 minutes, 10 minutes, 15 minutes) per point group. The conventional treatment group will receive mecobalamin tablets and alpha-lipoic acid tablets for four weeks in conjunction with the patient's daily treatment (basal drug treatment for patients with combined hypertension and hyperlipidaemia). The frequency of moxibustion treatment is twice a week for 4 weeks. The outcomes were evaluated in the baseline period (the day before grouping), the treatment period (end of the 8th treatment) and the follow-up period (2 weeks after the end of treatment). The results of this study are expected to confirm the optimal amount of moxibustion for the treatment of diabetic peripheral neuralgia and to observe the efficacy of moxibustion in the treatment of diabetic peripheral neuralgia. It provides a reference for the clinical therapeutic operation standardization of moxibustion. conditions: Diabetic Peripheral Neuropathy conditions: Pain conditions: Moxibustion conditions: Randomized Controlled Trial studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 132 type: ESTIMATED name: Moxibustion measure: Electrophysiological examination of the tibial nerve of the lower limb measure: Electrophysiological examination of the peroneal nerve of the lower limb measure: Total clinical effectiveness measure: Toronto Clinical Scoring System measure: Visual Analogue Scale measure: Traditional Chinese Medicine Syndrome Score Scale measure: regional temperature testing measure: infrared thermography testing sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06330220 id: 2010-015-1161 briefTitle: Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity overallStatus: COMPLETED date: 2021-02-10 date: 2022-02-28 date: 2022-02-28 date: 2024-03-26 date: 2024-03-26 name: Seoul National University Hospital class: OTHER briefSummary: Although the number of wet AMD patients with the better visual acuity is increasing, the visual improvement in patients with the better vision may not be so significant after anti-vascular endothelial growth factor (VEGF) treatments because of 'ceiling effect'. The aim of current study is to investigate the improvement of visual function after aflibercept treatments using microperimetry in wet AMD patients with the better baseline visual acuity (≥20/40). conditions: Age-Related Macular Degeneration studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ACTUAL name: Aflibercept Injection [Eylea] measure: Retinal sensitivity change after aflibercept treatment using microperimetry in wet age-related macular degeneration patients measure: The correlation of OCT and OCT angiography parameters with retinal sensitivity change measured by microperimetry sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Seoul National University Hospital city: Seoul zip: 03080 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06330207 id: IRB202301471 id: K99DE031723 type: NIH link: https://reporter.nih.gov/quickSearch/K99DE031723 briefTitle: An Emergency Department (ED) Provider Centered Intervention for Non-Traumatic Dental Condition Management (NTDC) overallStatus: NOT_YET_RECRUITING date: 2025-08-01 date: 2027-02-01 date: 2027-08-01 date: 2024-03-26 date: 2024-03-26 name: University of Florida class: OTHER name: National Institute of Dental and Craniofacial Research (NIDCR) briefSummary: The overall objective of this proposal is to understand the barriers and facilitators to non-traumatic dental condition (NTDC) management in the emergency department (ED) through quantitative and qualitative methods. The first aim will determine the national variation in NTDC prescribing in the ED and subsequent ED/urgent care revisits and hospitalizations within 30-days of an index ED visit. Using national electronic health records and integrated claims datasets and a random effects model, we will identify factors associated with prescribing for NTDC and variation at the patient, provider, hospital and state levels. The second aim identifies ED providers' perceived barriers and facilitators to the management of NTDC in the ED. Using individual in depth interviews, ED providers (physicians, advanced practice providers) will identify the facilitators and barriers to management and prescribing for NTDC in the ED. conditions: Emergency Department Visit conditions: Odontalgia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 60 type: ESTIMATED name: Clinical decision support tool measure: Acceptability and feasibility measure: Prescribing behavior measure: Pilot trial outcomes sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06330194 id: AID-study briefTitle: Next Generation Advanced Insulin Delivery System in Adults With Diabetes and Advanced Renal Disease overallStatus: RECRUITING date: 2024-04-18 date: 2024-12-31 date: 2024-12-31 date: 2024-03-26 date: 2024-04-22 name: Steno Diabetes Center Copenhagen class: OTHER name: Rigshospitalet, Denmark briefSummary: The goal of this this randomized, clinical trial is to test an automated insulin delivery system (AID) in people with type 1 or type 2 diabetes who are on hemodialysis, peritoneal dialysis, or have advanced chronic kidney disease (CKD).
Researchers will compare blood sugar levels between the AID group and the Control group to determine if the AID system is superior in regulating blood sugar levels. conditions: Dialysis conditions: Chronic Kidney Disease conditions: Diabetes Mellitus, Type 2 conditions: Diabetes Mellitus, Type 1 conditions: Hemodialysis conditions: Peritoneal Dialysis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Design: Prospective, open-label, two-stage randomised-crossover study.
CGM study outcome data will be collected by identical methods, using unblinded-CGM devices, for participants in both intervention and control study arms. primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: 2nd Generation Automated Insulin Delivery (AID) system measure: Percent time in sensor glucose target range (3.9-10.0 mmol/L) measure: Proportion of time spent <2.8 mmol/L measure: Proportion of time spent <3.0 mmol/L measure: Proportion of time spent <3.3 mmol/L measure: Proportion of time spent <3.9 mmol/L measure: Proportion of time spent 3.9-7.8 measure: Proportion of time spent >10.0 mmol/L measure: Proportion of time spent >13.9 mmol/L measure: Proportion of time spent >16.7 mmol/L measure: Glucose variability (SD and coefficient of variation) measure: Mean glucose measure: HbA1c measure: Episodes of CGM time in < 3.0 mmol/L range lasting >15 minutes measure: Diabetic ketoacidosis og Hyperosmolar non-ketotic hyperglycemia measure: eGFR (estimated glomerular filtration rate) measure: Potassium pre-dialysis measure: Urine albumine-to-creatinine ratio measure: Actigraph Metrics for sleep architecture measure: Sleep diary measure: Proportion of time Automode is active measure: Diabetic ketoacidosis measure: Severe hypoglycemia measure: Serious Adverse Event measure: Unanticipated Serious Adverse Device Event measure: Satisfaction with diabetes treatment measure: Satisfaction with diabetes treatment measure: Fear of hypoglycaemia measure: Hypoglycaemia awareness measure: Diabetes distress measure: Sleep Quality measure: Cognitive function measure: Sarcopenia measure: Semi-structured interview measure: Health-related quality of life measure: Frailty sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tobias Bomholt status: RECRUITING city: Copenhagen zip: 2100 country: Denmark name: Tobias Bomholt, MD, PhD role: CONTACT phone: +4535457952 email: Tobias.bomholt@regionh.dk name: Christine Meyer Olesen, MD role: CONTACT phone: 21495144 email: clmolesen@gmail.com lat: 55.67594 lon: 12.56553 hasResults: False